LOS ANGELES -- The association between menstrual cycle activity and breast and ovarian cancer risk may have an unexpected intermediary - odors.
Keck Medicine of USC researchers have discovered for the first time that the estrous cycle (the equivalent of human menstrual cycle) in mice carrying a mutation known to cause familial predisposition to breast and ovarian cancer in humans is more readily stimulated by scent than in normal mice. Even more surprising was the finding that the ovary, independently of the nose, mediated the olfactory signals.
"This research indicates that a better sense of smell may contribute to the elevated cancer risk of women with BRCA1 mutations," said corresponding author Louis Dubeau, professor of pathology and medical director of molecular pathology, USC Norris Comprehensive Cancer Center. "We found that the presence of the mutation in the ovary mediated a stronger response to scent, implying that the mutation may influence the menstrual cycle, which in turn is an established risk factor for breast and ovarian cancer."
The research will be published Oct. 21, 2015 in the peer-reviewed journal PLOS ONE (Public Library of Science).
Springing off the observation that menstrual cycles often synchronize between female college roommates, indicating some sort of communication with environmental signals, the scientists compared female mice genetically engineered to carry the BRCA1 mutation to normal, or wild-type mice. They isolated the females from males, causing estrous to pause in the females. When the females were exposed to male bedding, those with the BRCA1 mutation restarted estrous faster than the wild-type mice.
To confirm that the results were mediated by the ovary independently of the nose, the scientists transplanted ovaries from mice with the BRCA1 mutation into wild-type mice and also transplanted ovaries from normal mice into the genetically engineered mice carrying the mutation. The wild-type mice with the BRCA1 mutation present in their ovarian transplants responded more quickly when introduced to the male scent than mutant mice with wild-type ovarian transplants carrying the mutation in all tissues except the ovary.
"We've known for a long time that smell receptors are expressed in all kinds of tissues, but we know very little about what these receptors do outside of the nose," Dubeau said. "Only certain tissues in the breast and reproductive organs have an elevated cancer risk in women who carry a BRCA1 mutation. We found that BRCA1 mutations do not only influence these tissues directly, but also indirectly by changing how they communicate with other cells. This research is one of several examples shown in my laboratory where BRCA1 controls how different cells communicate from a distance. If we can understand how disruption in such communications leads to elevated cancer risk in BRCA1 mutation carriers, we can develop therapies to control these cancers, including perhaps therapies based on smell."
###
Other USC researchers who contributed to the study include Ying Liu, Yuan Tang, Elena Enbom and Theresa Austria (Department of Pathology, Keck School of Medicine of USC), Vasu Punj (USC Norris Comprehensive Cancer Center Bioinformatics Core and Division of Hematology), Frank Z. Stanczyk, Yvonne G. Lin and Sara Mucowski (Department of Obstetrics and Gynecology, Keck School of Medicine of USC), and Nancy Wu, Hai-Yun Yen and Robert Maxson (Department of Biochemistry and Microbiology, USC Dornsife College of Letters, Arts and Sciences). Other contributors include Malcolm C. Pike (Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center) and Martin Widschwendter (Department of Women's Cancer, University College, London, United Kingdom).
The research, "Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent," was funded by the National Institutes of Health (grants number R01 CA119078 and R01 CA133117).
Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, et al. (2015) Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLOS ONE 10(10): e0139013. doi: 10.1371/journal.pone.0139013
ABOUT KECK MEDICINE OF USC
Keck Medicine of USC is the University of Southern California's medical enterprise, one of only two university-based medical systems in the Los Angeles area. Encompassing academic, research and clinical excellence, the medical system attracts internationally renowned experts who teach and practice at the Keck School of Medicine of USC, the region's first medical school; includes the renowned USC Norris Comprehensive Cancer Center, one of the first comprehensive cancer centers established by the National Institutes of Health (NIH) in the United States; has a medical faculty practice, the USC Care Medical Group; operates the Keck Medical Center of USC, which includes two acute care hospitals: 401-licensed bed Keck Hospital of USC and 60-licensed bed USC Norris Cancer Hospital; and owns USC Verdugo Hills Hospital, a 158-licensed bed community hospital. It also includes more than 40 outpatient facilities, some at affiliated hospitals, in Los Angeles, Orange, Kern, Tulare and Ventura counties.
In 2015, U.S. News & World Report ranked Keck Medical Center of USC among the Top 10 in ophthalmology and among the Top 50 hospitals in the United States for urology and cancer care.
For more information, go to http://www.keckmedicine.org/beyond
Journal
PLOS ONE